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There is an increasing focus on intensive care
unit-acquired weakness, its underlying mechanisms
and therapeutic options. In this article we offer a
commentary on the paper by Bloch and colleagues
entitled 'MiR-181a: a potential biomarker of acute
muscle wasting following cardiac surgery'. There is a
need for biomarkers for intensive care unit-acquired
weakness, not only in clinical practice but also in order
to streamline future therapeutic trials. MicroRNAs are
attractive biomarkers, and may have an important role
in this disease. We highlight the significance of the
authors’ finding of miR-181a, a novel plasma biomarker
for the development of acute muscle wasting in
post-operative cardiac surgery patients and discuss
future research that is needed in this field following on
from the study findings.pression. MicroRNAs are potentially attractive as diseaseIn this issue of Critical Care, Bloch and colleagues report
on the utility of miR-181a estimation as a potential bio-
marker of acute muscle wasting following cardiac surgery
[1]. Intensive care unit-acquired weakness (ICUAW) is an
increasingly recognised consequence of critical illness. It is
both a common and major contributor to prolonged ICU
stay and impaired quality of life of the patients who sur-
vive to discharge from hospital [2]. The major risk factors
for developing ICUAW include sepsis, systemic inflamma-
tory response syndrome and multi-organ failure [3,4].
Other risk factors include uncontrolled hyperglycaemia
[5] and the use of glucocortoids and neuromuscular* Correspondence: d.thickett@bham.ac.uk
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unless otherwise stated.blocking agents [3,6]. A key feature of the disease is the
loss of muscle mass resulting from a shift in the dynamic
balance of muscle protein synthesis and breakdown and a
reduction in force generating capacity, which is associated
with prolonged weaning and ICU stay and disability in
survivors [7]. At present, the molecular mechanisms
underlying the muscle atrophy of ICUAW are not fully
understood. Recent work by Bloch and colleagues has
suggested that along with growth factors, microRNAs
may have an important role in ICUAW [8] and muscle
phenotype and atrophy in chronic obstructive pulmon-
ary disease [9,10].
A biomarker for ICUAW would be useful clinically
not only for diagnosis, prognostication and to guide
rehabilitation, but also in order to facilitate potential
future drug or interventional trials. A microRNA is a
small non-coding RNA molecule whose function is RNA
silencing and post-transcriptional regulation of gene ex-
biomarkers. There is increasing published literature on
the complex mechanisms of action of microRNAs, their
stability in plasma and relating their presence to disease
state and severity of disease progression [11]. Their role
in malignancy as both potential biomarker and therapeutic
target has been reviewed [12], and early therapeutic stud-
ies using microRNAs are underway in the field of rheu-
matology [13]. Bloch and colleagues hypothesised that
certain plasma microRNAs could be biomarkers of acute
muscle wasting. They measured plasma levels of selected
microRNAs pre- and post-operatively from a prospective
observational study of 42 patients undergoing high-risk
cardiothoracic surgery. Of these patients, 55% have been
previously described to develop muscle wasting defined by
measuring a cross-sectional area of the rectus femoris by
ultrasound.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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was significantly higher on the second post-operative day
in patients who developed sonographic muscle wasting at
1 week compared to those who did not. Physical strength
and rehabilitation were not assessed. They calculated that
a rise from baseline greater than 1.7 times in miR-181a
had 91% specificity and 56% sensitivity for subsequent
muscle wasting. The authors comment that the test's high
positive predictive value (91%) could be used to identify
those patients at risk, but could not exclude a diagnosis of
ICUAW because of its low sensitivity.
At present, the biological role of miR-181a is not fully
understood. It is expressed in muscle and elsewhere and
has been shown to be essential for muscle regeneration
and differentiation after tissue injury [14], and also has a
role in the regulation of inflammatory pathways [15].
More research is needed into the role of miR-181a and
indeed other microRNAs that may have roles in ICUAW.
It is possible miR-181a does not, as suggested by Bloch
and colleagues, represent damage itself, but may be pro-
moting the regeneration of muscle following the surgical
insult [1].
Future directions
The paper by Bloch and colleagues shows preliminary
evidence to suggest that mir-181a may be a potential
biomarker for the development of acute muscle wasting
in critically unwell patients. This is an intriguing possi-
bility, not only to allow insight into the structural and
functional changes of skeletal muscle during critical illness
but also to allow better targeting of current and novel
treatments, be that nutrition, physiotherapy, pharmaco-
therapy or external electrical stimulation. Further research
is needed to validate miR-181a as a biomarker in the wider
‘unselected’ ICU populations and its role in the changes
observed in skeletal muscle in critical illness. This paper
provides an exciting glimpse into ICUAW and future
directions for research.
Abbreviation
ICUAW: Intensive care unit-acquired weakness.
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